The Role of Complement in Dendritic Cell (DC ) Control of T-cell Subsets
November 2010 | Volume 9 | Issue 11 | Editorials | 1364 | Copyright © November 2010
William R. Levis MD and Frank Martiniukb PhD
Abstract
This section of the Journal of Drugs in Dermatology (JDD) is dedicated to Dendreon’s Provenge (Sipuleucel-T), the first therapeutic DC vaccine proven effective and approved by the United States (U.S.) Food and Drug Administration (FDA) for advanced cancer.1 This editorial will discuss three articles in this issue, their relationship to Provenge and the recent TH17-Treg subsets that are regulated by CD46.2 
